Search Results for: CLINICAL TRIALS Its Time to
Articles
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate March 8, 2022
Valneva SE recently announced the successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553....SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies March 1, 2022
Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.
FORMULATION DEVELOPMENT - Impact of Excipients & Manufacturing Process on Solubility-Enhanced Ritonavir Tablet Size & Weight Reduction March 1, 2022
Gayatri Khanvilkar, MPharm, Ajit Bhagat, and Tejas Gunjikar, PhD, investigate bulking agents and disintegrants to develop efficacious Rotonavir tablets with improved in vitro release.
GENE EDITING TECHNOLOGY - Harnessing a Cell’s Natural DNA Repair Process to Develop Medicines With Higher Levels of Precision & Durability March 1, 2022
Mariana Nacht, PhD, reviews a new gene editing approach that harnesses a cell’s natural DNA repair process, known as homologous recombination, to insert a corrective copy of the gene (or transgene) at a precise spot in a patient’s genome.
Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ Technology Can Identify T-Cell Receptors Associated With Crohn’s Disease February 18, 2022
Adaptive Biotechnologies Corporation recently presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation...Recipharm Announces Acquisition of Vibalogics & Arranta Bio February 18, 2022
Recipharm is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics and Arranta Bio….
Veru Announces the Presentation of Updated Data From Phase 1b/2 Sabizabulin Study in Men With Metastatic Castration Resistant Prostate Cancer February 17, 2022
Veru Inc. recently announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin in 80 men with...Revive Therapeutics Receives FDA Orphan Drug Designation February 16, 2022
Revive Therapeutics Ltd. recently announced the US FDA has granted Orphan Drug Designation (ODD) for Bucillamine for the prevention of...AC Immune & Janssen Pharmaceuticals Report Interim Results for Phase 2 Tau Vaccine Program February 15, 2022
AC Immune SA recently announced new interim 10-week data from the high-dose cohort of a placebo-controlled Phase 1b/2a trial evaluating ACI-35.030, a first-in-class phosphorylated-Tau (pTau) vaccine candidate in….
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma February 9, 2022
Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. recently announced positive in vivo data for PNV-5032, as a potential treatment for….
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19 February 7, 2022
Adamis Pharmaceuticals Corporation recently announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of….
ImCheck Announces First Patients Dosed in Phase 2 of EVICTION Trial for ICT01 February 3, 2022
ImCheck Therapeutics recently announced the first patients have been dosed in the Phase 2a monotherapy expansion arm in the ongoing...Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis & Secures $175 Million Credit Facility February 2, 2022
Tarsus Pharmaceuticals, Inc. recently announced it has completed enrollment of Saturn-2, the company’s second pivotal Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with….
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder January 27, 2022
Yamo Pharmaceuticals recently announced the first patient has been treated in a Phase 2 study of L1-79 in adolescents and...INmune Bio, Inc. Announces Research Collaboration With Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer January 25, 2022
INmune Bio, Inc. recently announced the company has entered into a preclinical research collaboration with Chinese University of Hong Kong...Biomea Fusion Announces First Patient Dosed January 25, 2022
Biomea Fusion, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with….
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder January 25, 2022
Mind Medicine (MindMed) Inc. recently announced the US FDA has cleared MindMed’s Investigational New Drug application, allowing the company’s Phase 2b dose-optimization trial of….
Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients January 24, 2022
Lyra Therapeutics, Inc. recently announced the initiation of the Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients, with trial sites open for….
Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients With Short Bowel Syndrome January 20, 2022
Zealand Pharma A/S recently announced completion of patient enrollment in its pivotal Phase 3 trial (EASE-SBS 1) of glepaglutide, the...Petros Pharmaceuticals Launches Two Self-Selection Studies for ED Drug January 18, 2022
Petros Pharmaceuticals, Inc. recently initiated two self-selection studies for its erectile dysfunction (ED) drug STENDRA (avanafil). The results of these...
